Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest announcement is out from Akebia Therapeutics ( (AKBA) ).
On November 28, 2025, Akebia Therapeutics acquired the global rights to ADX-097, a clinical-stage development candidate from Q32 Bio, for the treatment of rare kidney diseases. This acquisition, along with the establishment of a rare kidney disease pipeline, marks a significant step for Akebia, as it plans to initiate Phase 2 trials for both ADX-097 and praliciguat in 2026, aiming to address unmet needs in rare kidney diseases and strengthen its market position.
The most recent analyst rating on (AKBA) stock is a Buy with a $6.00 price target. To see the full list of analyst forecasts on Akebia Therapeutics stock, see the AKBA Stock Forecast page.
Spark’s Take on AKBA Stock
According to Spark, TipRanks’ AI Analyst, AKBA is a Neutral.
Akebia Therapeutics faces significant financial challenges, including declining revenue and high leverage. However, the strong launch of Vafseo and strategic market expansion provide some optimism. Despite these positive developments, the stock remains a risk due to ongoing financial instability and valuation challenges.
To see Spark’s full report on AKBA stock, click here.
More about Akebia Therapeutics
Akebia Therapeutics, Inc. is a biopharmaceutical company focused on improving the lives of individuals affected by kidney disease. Founded in 2007 and based in Cambridge, Massachusetts, Akebia develops treatments for kidney-related conditions, including anemia due to chronic kidney disease, with its product Vafseo® (vadadustat) approved in 37 countries.
Average Trading Volume: 4,239,023
Technical Sentiment Signal: Sell
Current Market Cap: $419.3M
For an in-depth examination of AKBA stock, go to TipRanks’ Overview page.